Company intelligence
Immuneering Corporation
Helping Cancer Patients Live Longer and Feel Better
About Immuneering Corporation
Immuneering is a clinical-stage oncology company focused on keeping cancer patients alive. The Company is developing an entirely new category of cancer medicines, Deep Cyclic Inhibitors. Immuneering’s lead product candidate, atebimetinib (IMM-1-104), is an oral, once-daily Deep Cyclic Inhibitor of MEK designed to improve durability and tolerability, and expand indications to include MAPK pathway-driven tumors such as most pancreatic cancers. Atebimetinib is currently in a Phase 2a trial in patients with advanced solid tumors including pancreatic cancer. The Company’s development pipeline also includes early-stage programs. For more information, please visit www.immuneering.com.
Verified activity
Signals from Immuneering Corporation
2 published signals
Presence & Recognition
Immuneering Corporation is attending and presenting at the 8th RAS-Targeted Drug Development Summit in Boston from September 8 to 10, 2026.
Reported by Immuneering Corporation
Presence & Recognition
Immuneering Corporation is gearing up for a busy Fall at Immuneering, starting with presentations and 1x1 meetings at two investor conferences in New York this month.
Reported by Immuneering Corporation